Download PDF
Semin Thromb Hemost 2016; 42(03): 185-190
DOI: 10.1055/s-0036-1571307
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Platelet Function Tests in Bleeding Disorders

Riitta Lassila
1   Coagulation Disorders, Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki University, Helsinki, Finland
› Author Affiliations
Further Information

Publication History

Publication Date:
17 February 2016 (online)

    Permissions and Reprints

Abstract

Functional disorders of platelets can involve any aspect of platelet physiology, with many different effects or outcomes. These include platelet numbers (thrombocytosis or thrombocytopenia); changes in platelet production or destruction, or capture to the liver (Ashwell receptor); altered adhesion to vascular injury sites and/or influence on hemostasis and wound healing; and altered activation or receptor functions, shape change, spreading and release reactions, procoagulant and antifibrinolytic activity. Procoagulant membrane alterations, and generation of thrombin and fibrin, also affect platelet aggregation. The above parameters can all be studied, but standardization and quality control of assay methods have been limited despite several efforts. Only after a comprehensive clinical bleeding assessment, including family history, information on drug use affecting platelets, and exclusion of coagulation factor, and tissue deficits, should platelet function testing be undertaken to confirm an abnormality. Current diagnostic tools include blood cell counts, platelet characteristics according to the cell counter parameters, peripheral blood smear, exclusion of pseudothrombocytopenia, whole blood aggregometry (WBA) or light transmission aggregometry (LTA) in platelet-rich plasma, luminescence, platelet function analysis (PFA-100) for platelet adhesion and deposition to collagen cartridges under blood flow, and finally transmission electron microscopy to exclude rare structural defects leading to functional deficits. The most validated test panels are included in WBA, LTA, and PFA. Because platelets are isolated from their natural environment, many simplifications occur, as circulating blood and interaction with vascular wall are omitted in these assays. The target to reach a highly specific platelet disorder diagnosis in routine clinical management can be exhaustive, unless needed for genetic counseling. The elective overall assessment of platelet function disorder primarily aims at better management of hemostasis in case of emergency surgery or other interventions and acute bleeding events.

Keywords

platelet procoagulant activity - aggregation - bleeding disorders
 

  • References

  • 1 Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev 2015; 29 (3) 153-162
    CrossrefPubMedGoogle Scholar
  • 2 Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev 2014; 28 (3) 95-102
    CrossrefPubMedGoogle Scholar
  • 3 Hurst BS, Lange SS, Kullstam SM , et al. Obstetric and gynecologic challenges in women with Ehlers-Danlos syndrome. Obstet Gynecol 2014; 123 (3) 506-513
    CrossrefPubMedGoogle Scholar
  • 4 Akkerman JW. Thrombopoietin and platelet function. Semin Thromb Hemost 2006; 32 (3) 295-304
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Regulating billions of blood platelets: glycans and beyond. Blood 2015; 126 (16) 1877-1884
    CrossrefPubMedGoogle Scholar
  • 6 Barsam SJ, Psaila B, Forestier M , et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011; 117 (21) 5723-5732
    CrossrefPubMedGoogle Scholar
  • 7 Ilveskero S, Siljander P, Lassila R. Procoagulant activity on platelets adhered to collagen or plasma clot. Arterioscler Thromb Vasc Biol 2001; 21 (4) 628-635
    CrossrefPubMedGoogle Scholar
  • 8 Hoffbrand AV, Moss PAH. Bleeding disorders caused by vascular and platelet abnormalities. In: Hoffbrand AV, Mos PAH, eds. Essential Hematology. 8th ed. Oxford, United Kingdom: Blackwell Publishing Ltd; 2011: 331-344
    Google Scholar
  • 9 Favaloro EJ. Internal quality control and external quality assurance of platelet function tests. Semin Thromb Hemost 2009; 35 (2) 139-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Du VX, Huskens D, Maas C, Al Dieri R, de Groot PG, de Laat B. New insights into the role of erythrocytes in thrombus formation. Semin Thromb Hemost 2014; 40 (1) 72-80
    PubMedGoogle Scholar
  • 11 Byrnes JR, Duval C, Wang Y , et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking. Blood 2015; 126 (16) 1940-1948
    CrossrefPubMedGoogle Scholar
  • 12 Lassila R, Jouppila A. Mast cell-derived heparin proteoglycans as a model for a local antithrombotic. Semin Thromb Hemost 2014; 40 (8) 837-844
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Marcus AJ, Broekman MJ, Drosopoulos JH , et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005; 31 (2) 234-246
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (8) 865-883
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Tutwiler V, Madeeva D, Ahn HS , et al. Platelet transactivation by monocytes promotes the prothrombotic state in heparin-induced thrombocytopenia. Blood 2016; 127 (4) 464-472
    CrossrefPubMedGoogle Scholar
  • 16 Liebman HA. Viral-associated immune thrombocytopenic purpura. Hematology (Am Soc Hematol Educ Program) 2008; 1: 212-218
    PubMedGoogle Scholar
  • 17 Laine O, Joutsi-Korhonen L, Lassila R , et al. Hantavirus infection-induced thrombocytopenia associates with impaired platelet aggregation but increases platelet production and secures platelet deposition under blood flow. Thromb Res 2015; (6); 136: 1126-1132
    CrossrefPubMedGoogle Scholar
  • 18 Zaffuto BJ, Conley GW, Connolly GC , et al. ABO-immune complex formation and impact on platelet function, red cell structural integrity and haemostasis: an in vitro model of ABO non-identical transfusion. Vox Sang 2015; ; 10.1111/vox.12354 (e-pub ahead of print)
    PubMedGoogle Scholar
  • 19 Phillips DR, Teng W, Arfsten A , et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96 (5) 1488-1494
    CrossrefPubMedGoogle Scholar
  • 20 Peerschke EI, Castellone DD, Stroobants AK, Francis J. Reference range determination for whole-blood platelet aggregation using the Multiplate analyzer. Am J Clin Pathol 2014; 142 (5) 647-656
    CrossrefPubMedGoogle Scholar
  • 21 Duncan EM, Bonar R, Rodgers SE, Favaloro EJ, Marsden K ; RCPA QAP in Haematology, Haemostasis Committee. Methodology and outcomes of platelet aggregation testing in Australia, New Zealand and the Asia-Pacific region: results of a survey from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program. Int J Lab Hematol 2009; 31 (4) 398-406
    CrossrefPubMedGoogle Scholar
  • 22 Gresele P, Harrison P, Bury L , et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost 2014; 12 (9) 1562-1569
    CrossrefPubMedGoogle Scholar
  • 23 Szántó T, Joutsi-Korhonen L, Deckmyn H, Lassila R. New insights into von Willebrand disease and platelet function. Semin Thromb Hemost 2012; 38 (1) 55-63
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Hayward CPM, Pai M, Liu Y , et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost 2009; 7 (4) 676-684
    CrossrefPubMedGoogle Scholar
  • 25 Estcourt LJ, Stanworth SJ, Harrison P , et al. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study. Br J Haematol 2014; 166 (4) 581-591
    CrossrefPubMedGoogle Scholar
  • 26 Rand ML, Perry DW, Packham MA, Gemmell CH, Yeo EL, Kinlough-Rathbone RL. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 1996; 52 (4) 288-294
    CrossrefPubMedGoogle Scholar
  • 27 Israels SJ. Laboratory testing for platelet function disorders. Int J Lab Hematol 2015; 37 (Suppl. 01) 18-24
    CrossrefPubMedGoogle Scholar
  • 28 Christie DJ, Avari T, Carrington LR , et al. Platelet Function Testing by Aggregometry; Approved Guideline. CLSI document H58-A. Wayne, PA: Clinical and Laboratory Standards Institute (CLSI); 2008
    Google Scholar
  • 29 Wartiovaara-Kautto U, Joutsi-Korhonen L, Ilveskero S, Armstrong E, Lassila R. Platelets significantly modify procoagulant activities in haemophilia A. Haemophilia 2011; 17 (5) 743-751
    PubMedGoogle Scholar
  • 30 Colace TV, Fogarty PF, Panckeri KA, Li R, Diamond SL. Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels. J Thromb Haemost 2014; 12 (2) 147-158
    CrossrefPubMedGoogle Scholar
  • 31 Scavone M, Germanovich K, Femia EA, Cattaneo M. Usefulness of the INNOVANCE PFA P2Y test cartridge for the detection of patients with congenital defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Res 2014; 133 (2) 254-256
    CrossrefPubMedGoogle Scholar